$435 Million is the total value of Cormorant Asset Management, LP's 46 reported holdings in Q1 2014. The portfolio turnover from Q4 2013 to Q1 2014 was 161.5% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
MDVN | Buy | MEDIVATION INC | $38,622,000 | +10.7% | 600,000 | +9.7% | 8.88% | -12.3% |
PBYI | Buy | PUMA BIOTECHNOLOGY INC | $21,609,000 | +4.4% | 207,500 | +3.8% | 4.97% | -17.3% |
BMRN | Buy | BIOMARIN PHARMACEUTICAL INC | $20,463,000 | +190.9% | 300,000 | +200.0% | 4.70% | +130.4% |
RCPT | Buy | RECEPTOS INC | $18,873,000 | +86.0% | 450,000 | +28.6% | 4.34% | +47.4% |
ICPT | New | INTERCEPT PHARMACEUTICALS IN | $16,490,000 | – | 50,000 | +100.0% | 3.79% | – |
ARWR | Buy | ARROWHEAD RESEARCH CORP | $16,420,000 | +52.0% | 1,000,000 | +0.5% | 3.78% | +20.4% |
PTCT | Buy | PTC THERAPEUTICS INC | $14,377,000 | +2840.1% | 550,000 | +1809.7% | 3.31% | +2228.2% |
JAZZ | New | JAZZ PHARMACEUTICALS PLC | $13,868,000 | – | 100,000 | +100.0% | 3.19% | – |
PRTA | New | PROTHENA CORP PLC | $13,409,000 | – | 350,000 | +100.0% | 3.08% | – |
BCRX | Buy | BIOCRYST PHARMACEUTICALS INC | $12,357,000 | +506.6% | 1,168,000 | +335.8% | 2.84% | +380.7% |
MRK | New | MERCK & CO. INC NEW | $11,354,000 | – | 200,000 | +100.0% | 2.61% | – |
SGMO | Buy | SANGAMO BIOSCIENCES INC | $10,848,000 | +369.8% | 600,000 | +261.0% | 2.49% | +272.2% |
SRNE | New | SORRENTO THERAPEUTICS INC | $8,974,000 | – | 700,000 | +100.0% | 2.06% | – |
ALKS | New | ALKERMES PLC | $8,818,000 | – | 200,000 | +100.0% | 2.03% | – |
KPTI | Buy | KARYOPHARM THERAPEUTICS INC | $8,649,000 | +277.4% | 280,000 | +180.0% | 1.99% | +199.1% |
CLVS | Buy | CLOVIS ONCOLOGY INC | $8,312,000 | +15.6% | 120,000 | +0.6% | 1.91% | -8.4% |
NSTG | New | NANOSTRING TECHNOLOGIES INC | $8,260,000 | – | 400,000 | +100.0% | 1.90% | – |
GLYC | New | GLYCOMIMETICS INC | $7,665,000 | – | 469,400 | +100.0% | 1.76% | – |
CMRX | Buy | CHIMERIX INC | $6,852,000 | +217.1% | 300,000 | +109.8% | 1.58% | +151.4% |
OMER | New | OMEROS CORP | $6,035,000 | – | 500,000 | +100.0% | 1.39% | – |
GALT | New | GALECTIN THERAPEUTICS INC | $5,328,000 | – | 348,000 | +100.0% | 1.22% | – |
PTLA | Buy | PORTOLA PHARMACEUTICALS INC | $5,180,000 | +168.3% | 200,000 | +166.7% | 1.19% | +112.7% |
EGRX | New | EAGLE PHARMACEUTICALS INC | $5,100,000 | – | 400,000 | +100.0% | 1.17% | – |
RMTI | New | ROCKWELL MED INC | $5,064,000 | – | 400,000 | +100.0% | 1.16% | – |
REPH | New | RECRO PHARMA INC | $3,660,000 | – | 500,000 | +100.0% | 0.84% | – |
GNVC | New | GENVEC INC | $3,523,000 | – | 1,329,300 | +100.0% | 0.81% | – |
AGEN | New | AGENUS INC | $3,170,000 | – | 1,000,000 | +100.0% | 0.73% | – |
AQXP | New | AQUINOX PHARMACEUTICALS INC | $3,143,000 | – | 246,877 | +100.0% | 0.72% | – |
ASPX | New | AUSPEX PHARMACEUTICALS INC | $3,076,000 | – | 100,000 | +100.0% | 0.71% | – |
BIIB | New | BIOGEN IDEC INC | $3,059,000 | – | 10,000 | +100.0% | 0.70% | – |
RARE | New | ULTRAGENYX PHARMACEUTICAL IN | $2,933,000 | – | 60,000 | +100.0% | 0.67% | – |
RGLS | Buy | REGULUS THERAPEUTICS INC | $1,804,000 | +144.1% | 200,000 | +100.0% | 0.42% | +93.9% |
IDRA | New | IDERA PHARMACEUTICALS INC | $1,632,000 | – | 400,000 | +100.0% | 0.38% | – |
CLTX | New | CELSUS THERAPEUTICS PLCsponsored adr ne | $668,000 | – | 103,000 | +100.0% | 0.15% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2014-05-15
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
QUOTIENT LTD | 30 | Q3 2021 | 4.3% |
ASCENDIS PHARMA A/S | 30 | Q4 2022 | 4.8% |
MINERVA NEUROSCIENCES INC | 29 | Q3 2021 | 4.4% |
ACCELERON PHARMA INC | 28 | Q2 2021 | 3.4% |
OMEROS CORP | 27 | Q3 2021 | 6.5% |
MIRATI THERAPEUTICS INC | 25 | Q4 2022 | 7.6% |
BLUEPRINT MEDICINES CORP | 25 | Q3 2021 | 3.6% |
APELLIS PHARMACEUTICALS INC | 24 | Q3 2023 | 8.6% |
NEUROCRINE BIOSCIENCES INC | 24 | Q1 2020 | 4.6% |
ROCKET PHARMACEUTICALS, INC | 23 | Q3 2023 | 2.4% |
View Cormorant Asset Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Ambrx Biopharma Inc. | March 13, 2023 | 42,771,365 | - |
Altimmune, Inc. | February 14, 2023 | 2,600,000 | - |
Arcellx, Inc. | February 14, 2023 | 2,075,000 | - |
BioAtla, Inc. | February 14, 2023 | 2,499,250 | - |
Eledon Pharmaceuticals, Inc. | February 14, 2023 | 1,391,663 | - |
GreenLight Biosciences Holdings, PBC | February 14, 2023 | 4,751,020 | - |
Prometheus Biosciences, Inc. | February 14, 2023 | 700,000 | - |
Tango Therapeutics, Inc. | February 14, 2023 | 1,000,000 | - |
VectivBio Holding AG | February 14, 2023 | 1,515,087 | - |
Viridian Therapeutics, Inc.\DE | February 14, 2023 | 1,100,000 | - |
View Cormorant Asset Management, LP's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-05-15 |
SC 13G | 2024-05-13 |
4 | 2024-05-08 |
SC 13G | 2024-04-29 |
4 | 2024-04-22 |
SC 13G/A | 2024-04-15 |
4 | 2024-04-03 |
SC 13G | 2024-03-21 |
4 | 2024-03-18 |
SC 13G/A | 2024-03-18 |
View Cormorant Asset Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.